News Archive - GOG https://www.gog.org/news/ Gog Fri, 23 Oct 2026 19:32:20 +0000 en-US hourly 1 GOG-3107 | ENGOT-ov86 | RAINFOL-02Press Release https://www.gog.org/news/gog-3107-engot-ov86-rainfol-02press-release/ Fri, 23 Oct 2026 19:32:20 +0000 https://www.gog.org/?post_type=news&p=9699 PRESS RELEASE For Immediate Release Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival […]

The post GOG-3107 | ENGOT-ov86 | RAINFOL-02<br>Press Release</br> appeared first on GOG.

]]>

PRESS RELEASE

For Immediate Release

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

COPENHAGEN, Denmark; October 23, 2026:

  • Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice chemotherapy
  • Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC)
  • Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide

Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival (PFS), with Rina-S demonstrating a statistically significant and clinically meaningful improvement compared with investigator’s choice chemotherapy in the intent-to-treat (ITT) and in the primary analysis set (PAS) populations.

Click here to read the full press release.

The post GOG-3107 | ENGOT-ov86 | RAINFOL-02<br>Press Release</br> appeared first on GOG.

]]> GOG-3066 | DENALIPress Release https://www.gog.org/news/gog-3066-denalipress-release/ Fri, 23 Oct 2026 19:25:00 +0000 https://www.gog.org/?post_type=news&p=9697 PRESS RELEASE For Immediate Release Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients […]

The post GOG-3066 | DENALI<br>Press Release</br> appeared first on GOG.

]]>

PRESS RELEASE

For Immediate Release

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial (NCT07546500, GOG-3147, ENGOT-ov109, APGOT-OV27) evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC).

“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and ASPENOVA now enrolling to evaluate azenosertib versus standard-of-care chemotherapy to support full approval, we are executing on a comprehensive development and regulatory strategy designed to bring this therapy to patients as quickly as possible. We are deeply grateful to the patients participating in this important trial and to our collaborators at The GOG Foundation, Inc. (GOG-F), ENGOT, and APGOT for their partnership in advancing this research.”

Click here to read the full press release.

The post GOG-3066 | DENALI<br>Press Release</br> appeared first on GOG.

]]> Society of Pelvic Surgeons Selects (SPS) The GOG Foundation, Inc. (GOG-F) as Management Partner to Advance Multidisciplinary Surgical Collaboration Worldwide Press Release https://www.gog.org/news/society-of-pelvic-surgeons-selects-sps-the-gog-foundation-inc-gog-f-as-management-partner-to-advance-multidisciplinary-surgical-collaboration-worldwide-press-release/ Tue, 15 Sep 2026 14:48:40 +0000 https://www.gog.org/?post_type=news&p=9604 PRESS RELEASE For Immediate Release Society of Pelvic Surgeons Selects (SPS) The GOG Foundation, Inc. (GOG-F) as Management Partner to […]

The post Society of Pelvic Surgeons Selects (SPS) <br>The GOG Foundation, Inc. (GOG-F) as Management Partner to Advance Multidisciplinary Surgical Collaboration Worldwide Press Release</br> appeared first on GOG.

]]>

PRESS RELEASE

For Immediate Release

Society of Pelvic Surgeons Selects (SPS) The GOG Foundation, Inc. (GOG-F) as Management Partner to Advance Multidisciplinary Surgical Collaboration Worldwide

Philadelphia, PA, September 15, 2026 — The GOG Foundation, Inc., a nonprofit organization dedicated to advancing clinical research and improving outcomes for patients with gynecologic cancers, today announced that it has assumed management responsibilities for the Society of Pelvic Surgeons (SPS), a distinguished global organization that brings together experts in gynecology, urology, and colorectal surgery to advance the science and practice of pelvic surgery.

Founded on the principle that collaboration across specialties improves patient care, the SPS has served as a unique forum for surgeons from around the world to share innovations, research findings, and clinical expertise. Through its annual scientific meetings, such as the upcoming one taking place October 7-10, 2026, in Banff, Alberta, Canada and active international membership, SPS fosters multidisciplinary education and promotes the exchange of ideas that lead to advances in diagnosis, treatment, and surgical techniques.

Click here to read the full press release.

The post Society of Pelvic Surgeons Selects (SPS) <br>The GOG Foundation, Inc. (GOG-F) as Management Partner to Advance Multidisciplinary Surgical Collaboration Worldwide Press Release</br> appeared first on GOG.

]]> GOG-3132 | ENGOT-ov98 BEHOLD-Ovarian01Press Release https://www.gog.org/news/gog-3132-engot-ov98-behold-ovarian01press-release/ Mon, 27 Jul 2026 19:11:35 +0000 https://www.gog.org/?post_type=news&p=9398 PRESS RELEASE For Immediate Release First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, […]

The post GOG-3132 | ENGOT-ov98 BEHOLD-Ovarian01<br>Press Release</br> appeared first on GOG.

]]>

PRESS RELEASE

For Immediate Release

First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer

Philadelphia, PA, USA, July 27, 2026 – The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer. The study is sponsored by GSK and conducted in collaboration with The GOG Foundation, Inc.

Dr. Floor Backes, Principal Investigator of GOG-3132/BEHOLD-Ovarian01 and gynecologic oncologist at The Ohio State University Comprehensive Cancer Center, stated, “We are pleased to announce the enrollment of the first patient in BEHOLD-Ovarian01, an important milestone in the clinical development of mocertatug rezetecan. Building on the encouraging activity observed in the phase 1 BEHOLD-1 study, this Phase 3 trial will help determine whether B7-H4–targeted therapy can improve outcomes for patients with platinum-resistant ovarian cancer, an area of significant unmet medical need.”



Click here to read the full press release.

The post GOG-3132 | ENGOT-ov98 BEHOLD-Ovarian01<br>Press Release</br> appeared first on GOG.

]]> ENGOT-EN6-NSGO/GOG-3031/RUBY IJGC Publication https://www.gog.org/news/engot-en6-nsgo-gog-3031-ruby-ijgc-publication/ Fri, 24 Jul 2026 18:46:18 +0000 https://www.gog.org/?post_type=news&p=9390 Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus […]

The post ENGOT-EN6-NSGO/GOG-3031/RUBY IJGC Publication appeared first on GOG.

]]> Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

Click here to read the full publication.

 

 

 

The post ENGOT-EN6-NSGO/GOG-3031/RUBY IJGC Publication appeared first on GOG.

]]> GOG-3064/​ENGOT-en15 MK-3475-C93/​KEYNOTE-C93Press Release https://www.gog.org/news/gog-3064-engot-en15-mk-3475-c93-keynote-c93press-release/ Fri, 24 Jul 2026 18:42:38 +0000 https://www.gog.org/?post_type=news&p=9388 PRESS RELEASE For Immediate Release KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or […]

The post GOG-3064/​ENGOT-en15 MK-3475-C93/​KEYNOTE-C93<br>Press Release</br> appeared first on GOG.

]]>

PRESS RELEASE

For Immediate Release

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

 

On July 15, 2026:RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence more than six months after completing prior adjuvant therapy. KEYTRUDA is the first and only PD-1 inhibitor to show a statistically significant and clinically meaningful improvement in PFS as monotherapy compared to platinum doublet chemotherapy for these patients in a Phase 3 trial.

Click here to read full Merck press release.

 

The post GOG-3064/​ENGOT-en15 MK-3475-C93/​KEYNOTE-C93<br>Press Release</br> appeared first on GOG.

]]> GOG-3076/On Prime Gynecologic Oncology Reports Publication https://www.gog.org/news/gog-3076-on-prime-gynecologic-oncology-reports-publication/ Fri, 24 Jul 2026 18:38:46 +0000 https://www.gog.org/?post_type=news&p=9386 Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer Highlights Synergistic antitumor effects from Olvi-Vec and cisplatin were […]

The post GOG-3076/On Prime Gynecologic Oncology Reports Publication appeared first on GOG.

]]> Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer
Highlights
  • Synergistic antitumor effects from Olvi-Vec and cisplatin were demonstrated in a mouse model of PROC.
  • We studied changes in the TME following Olvi-Vec treatment in patients with PRROC.
  • IHC analysis showed an influx of CD4+ and CD8+ TILs in post-Olvi-Vec-infected tumor tissues.
  • Olvi-Vec-primed immunochemotherapy resulted in improved PFS compared to the last line of therapy in PRROC.

Click here to read the full publication.

 

 

The post GOG-3076/On Prime Gynecologic Oncology Reports Publication appeared first on GOG.

]]> Joint GOG & ENGOT Publication July 2026 https://www.gog.org/news/joint-gog-engot-publication-july-2026/ Mon, 06 Jul 2026 15:49:24 +0000 https://www.gog.org/?post_type=news&p=9355 Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners […]

The post Joint GOG & ENGOT Publication July 2026 appeared first on GOG.

]]> Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners
Highlights
  • Updated joint GOG Foundation and the European Network of Gynaecological Oncological Trial Groups (GOG-ENGOT) publication and authorship guidelines (Version 2.0), representing a comprehensive revision of the authorship provisions of the 2019 co-branded trial framework, developed and approved by the GOG/ENGOT Liaison Committee.
  • Formalization of the Third-Party Group designation, establishing defined authorship rights and accrual-based allocation rules for cooperative groups and consortia beyond GOG and ENGOT participating in co-branded gynecologic oncology trials.
  • Granular, accrual-proportional authorship calculation and positioning rules for primary analyses, secondary endpoint manuscripts, ancillary and translational research projects, and conference presentations, with explicit provisions to prevent accrual demotivation.
  • Designation of the GOG/ENGOT Liaison Committee as the arbiter for provisional queries and deviations from these guidelines.

Click here to read the full publication.

 

 

The post Joint GOG & ENGOT Publication July 2026 appeared first on GOG.

]]> GOG Partners Connection Quarterly Newsletter – April 2026 https://www.gog.org/news/gog-partners-connection-quarterly-newsletter-april-2026/ Sat, 18 Apr 2026 15:01:43 +0000 https://www.gog.org/?post_type=news&p=8911 The GOG Partners Connection Quarterly Newsletter is now available! Click here to download a PDF copy of the GOG Partners […]

The post GOG Partners Connection Quarterly Newsletter – April 2026 appeared first on GOG.

]]> The GOG Partners Connection Quarterly Newsletter is now available!

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

 

 

 

The post GOG Partners Connection Quarterly Newsletter – April 2026 appeared first on GOG.

]]> Accrual Culture: Top Points for Site Selection – Timelines https://www.gog.org/news/accrual-culture-top-points-for-site-selection-timelines/ Thu, 02 Apr 2026 22:34:10 +0000 https://www.gog.org/?post_type=news&p=8913 The GOG’s Accrual Culture series—Top Points for Site Selection—is available now! Access this new episode here: Access on GOG GYN-LIVE Podcast Access […]

The post Accrual Culture: Top Points for Site Selection – Timelines appeared first on GOG.

]]> The GOG’s Accrual Culture series—Top Points for Site Selection—is available now!

Access this new episode here:

Access on GOG GYN-LIVE Podcast

Access on YouTube

The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:
Corecept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem

The post Accrual Culture: Top Points for Site Selection – Timelines appeared first on GOG.

]]>